Ground-level proof points accumulating: management narrates several small, named, recent wins and treats them as the lea
The model's full reasoning — Q1 2016 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management's account rests on several small concrete ground-level wins individually named/described, and explicitly treats as leading edge of broader improvement still early. Transcript: Curis Q1 2016. Programs: CUDC-907 Phase 2 trial ongoing, Phase 1 results. CA170 entering clinic. Erivedge partner initiated two studies. Financials. Need identify episodes from recent period. Management mentions: - Completed enrollment in monotherapy arm of Phase 1 CUDC-907; 25 patients, 8 objective responses out of 19 evaluable. This is an aggregate trial result, not ground-level episode? It's a milestone but not individual customer/site. - Retrospective analysis indicates clinical benefit related to MYC inhibition; correlation. That's a finding. - Designed Phase 2 to treat MYC altered DLBCL; ongoing. - Solid tumor Phase 1 limited enrollment to MYC altered or NUT midline carcinoma. - CA170 expected to enter clinic later this quarter. That's future, not happened. - Roche initiated enrollment in two clinical studies with Erivedge outside BCC: one in myelofibrosis with ruxolitinib, one in IPF with pirfenidone. These are specific recent episodes: Roche initiated enrollment in two studies. Are these "wins"? They are partner-initiated studies, not necessarily business wins but concrete events. - Financial results: net loss, revenues, expenses. Question asks: "management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from inside the business, each one identifiable on its own — AND does management explicitly treat these accumulating episodes as the LEADING EDGE of a broader improvement that is still early?" Need answer YES only if both halves. Here management's positive story is mostly about clinical trial progress, not "wins" like customers. Episodes: completion of enrollment in Phase 1 monotherapy arm, retrospective analysis, Phase 2 initiation, CA170 expected entry, Roche initiated two studies. Are these "small concrete ground-level wins"? They are specific events. But are they "wins"? Maybe. However, management does not explicitly connect them into a broader improvement still early. They describe progress but not as leading edge of broader improvement. Also many are future/plans.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
AU · Q2 2018 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple specific, recent operational episodes: Kibali’s underground ramp-up with automated ore handling system and vertical shaft integration; Iduapriem’s CIL tank conversion and grade/tonnage gains; Sunrise Dam’s Recovery Enhancement Project plus new mining strategies; Tropicana’s second 6-MW ball mill installation; Siguiri’s CIL circuit milestone; and 338 tracked Operational Excellence projects.
BXP · Q1 2022 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple distinct, named episodes from the recent period: the 73,000 sq ft recapture/release at 77 CityPoint with a 15% rent increase and 7.
CRGO · Q1 2024 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...